SU
Sun Pharma
SUNPHARMA.NS·NSEMumbai INFounded 198338,000 employees
Large CappharmaPublicDermatologyOncologyOphthalmology
Platform: Specialty
Market Cap
$45B
All Drugs
9
Clinical Trials
13
Failed / Terminated
5
FDA Approved
1
Stock Price & Catalysts (SUNPHARMA.NS)
Loading SUNPHARMA.NS stock data...
Drug Pipeline (9 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gelibrutinib | SUN-2382 | NDA/BLA | 1 | EZH2 | ETMDD | ||
| Zoribrutinib | SUN-9626 | Preclinical | 1 | B7-H3 | NBLGS | ||
| Fixarapivir | SUN-7507 | Preclinical | 1 | CD3 | WilmsCKD | ||
| Nidatenlimab | SUN-6073 | NDA/BLA | 2 | KRASG12D | CLLBreast Ca | ||
| Sotosacituzumab | SUN-2578 | Approved | 2 | WRN | Breast Ca | ||
| Sotoratamab | SUN-402 | Phase 2 | 2 | GLP-1R | PNHCLL | ||
| SUN-5027 | SUN-5027 | Preclinical | 1 | DLL3 | PompeRSV | ||
| Zanuosocimab | SUN-3679 | Phase 3 | 2 | IL-17A | SLE | ||
| Zorizumab | SUN-2672 | Phase 1 | 1 | MDM2 | Obesity |
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Sun Pharma trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (15)